Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older
Latest Information Update: 28 Jun 2023
At a glance
- Drugs SP 0253 (Primary) ; Adjuvants
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Sanofi; Sanofi Pasteur
Most Recent Events
- 23 Dec 2021 Status changed from active, no longer recruiting to completed.
- 01 Sep 2021 Interim results reporting safety and immunogenicity data up to 43 days after the first vaccination published in The Lancet Infectious Diseases
- 27 May 2021 According to a Sanofi media release, first results from this study are expected in the third quarter of 2021.